News Releases

July, 2019

July 10, 2019 2019-07-10 Health Canada has authorized VYVANSE® (lisdexamfetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder (ADHD)

June, 2019

June 13, 2019 2019-06-13 Pedalling in support of rare disease research

March, 2019

March 11, 2019 2019-03-11 Takeda Canada announces positive results for ENTYVIO®(2)

March 1, 2019 2019-03-01 Takeda Canada commemorates Rare Disease Day with the launch of video patient stories

February, 2019

February 4, 2019 2019-02-04 Takeda Canada Recognized as Top Employer

January, 2019

January 10, 2019 2019-01-10 global acquisition of Shire Completed

November, 2018

November 23, 2018 2018-11-23 Takeda Canada and Game Yuceland Featured in CPM

October, 2018

October 23, 2018 2018-10-23 ENTYVIO® study data achieves and maintains clinical remission and mucosal healing in moderately to severely active ulcerative colitis